Seeking feedback on improvements to the recalls process

Closed 13 Mar 2023

Opened 30 Jan 2023

Feedback updated 26 Mar 2024

We asked

In 2023, we consulted widely on potential changes to how we undertake product recalls in Australia as part of ongoing reforms. Our discussion paper asked a series of questions around 5 key themes:

  • Increasing awareness and understanding
  • Improving communication
  • Better recall descriptions
  • Improving sponsor letters and other recall documents, and
  • Reporting progress with recalls

These themes aligned with aspects of the recall process that stakeholders were advising us required the most attention. The discussion paper sought responses about the proposed changes, as well as providing the opportunity for stakeholders to have their say about any other ideas.

You said

71 separate responses were received in total.

The Consultation responses were published in June 2023. 62 of the 71 responses consented to appearing (or partially appearing) on the TGA Consultation Hub, with 9 responses not consenting to be published.

View submitted responses where consent has been given to publish the response.

The proposals which received the broadest stakeholder support related to improvements to the recall and stakeholder communication processes and our guidance material. Respondents recommended that we:

  • reduce regulatory burden by limiting unnecessary steps in the process
  • ensure recall letters and notices are easy to read and have the key information up front so customers and other end users know exactly what to do
  • provide greater transparency on our processes, including clarity around the timing for releasing recall information and our process for assessing the hazard classification of recall actions
  • update our recall document templates
  • change the focus of the Customer Acknowledgement Form to a Customer Response Form and include modern options such as QR Codes and online survey links to improve customer response rates to some sponsor recall letters, and
  • give sponsors the opportunity to review the content of our Early Advice Notices prior to us seeking feedback from impacted stakeholders about aspects of the recall action before it is agreed.

We did

To support these recommendations, we have made changes to the recall processes which will now be implemented via a new version of our guidance document, the Uniform Recall Procedure for Therapeutic Goods (URPTG) Version 2.4, which has just been published on our website. The key reforms which have been implemented addressing the above recommendations are:

Process changes

  • We have reduced regulatory burden by decreasing the number of recall progress reports from 3 to 2
  • We have introduced more flexible reporting requirements for sponsor submissions of the 2 reports
  • The number of steps in the recall procedure has been reduced from 11 to 10.
  • The ‘Early Advice Notice’ process has been expanded to include additional stakeholders such as patient support groups and health professional guilds, where appropriate. We will give sponsors the opportunity to review the content. 
  • For recall actions involving ‘therapeutic goods’ which are also ‘consumer goods’, we have provided new guidance on the ‘lead regulator’ role – either the TGA or the Australian Competition and Consumer Commission (ACCC).

Changes to improve clarity and readability of the URPTG

  • The recall action templates have been updated so they are easier to read and with key information up front. They have been removed from the URPTG, and instead hyperlinks included to our website directing users to the most up-to-date versions.
  • The process we follow for releasing recall information has been clarified providing greater transparency.
  • Clarity on the use of the ‘Early Advice Notice’ process has been included in the updated URPTG.
  • Several sections have been re-written to be more concise and readable, including the process for undertaking “immediate recalls” and conducting a risk analysis.
  • We have reduced the URPTG by over 20 pages by removing outdated or repeated guidance.

What's next?

Our reform work continues. One of the most endorsed proposals from our consultation paper was the new recall terminology. We will implement this when several supporting IT infrastructure changes are made to our systems. When this occurs, the new terminology and further reforms will be included in a new update to the URPTG.

We will also review:

  • if further improvements can be made to our communication strategies and
  • whether our existing legislative recall powers are supporting effective recall processes.

We will provide further updates as our reforms progress throughout 2024.

Published responses

View submitted responses where consent has been given to publish the response.

Overview

The Therapeutic Goods Administration (TGA) is seeking feedback on improvements to the therapeutic goods recalls process.

In Australia, recalls should be done in accordance with the procedures in our guidance document - the Uniform Recall Procedure for Therapeutic Goods (URPTG)Performing recalls in accordance with standardised and agreed procedures is important to effectively respond to issues with therapeutic goods which may pose a risk to public health and safety, and efficiently communicate information in the right way.

The URPTG has been in place for many years and while it has been effective, there have been changes to our regulatory landscape over time. There are new types of products being used, increased complexity in supply chains and changes to the ways in which we communicate.

Based on feedback and information from both internal and external stakeholders, we have reviewed the current recall process and identified some potential improvements. 

We want to know what you think about our proposed changes. We have grouped these into five themes:

  1. Increasing awareness and understanding about recalls
  2. Improving communication
  3. Better recall descriptions
  4. Improving sponsor letters and other recall documents
  5. Reporting progress with a recall

We also welcome any other comments or suggestions you would like to provide.

Discussion Paper

The discussion paper gives further details about the current recalls process for therapeutic goods and the proposed improvements.

Therapeutic Goods Recall Processes - Discussion Paper

 

Why your views matter

If recalls are not performed in the right way, it could have a negative impact on patient's and consumer's health.

Our role is important in the oversight of therapeutic good recalls in Australia. We are investigating a range of potential improvements to the way recalls are managed. These changes could help improve health outcomes for patients and consumers, by reducing the risk posed from unsafe products.

However, before implementing any changes, we need your feedback to confirm the proposals will deliver the intended benefits, or details on how best to implement them.

We want input from all stakeholders who may be involved in the recall process. This includes industry, their customers, state and territory health departments, health professionals, healthcare organisations, wholesalers and retailers, consumers and patients and associated support groups.

What happens next

Submissions will be reviewed by the TGA. A summary of responses will be published and all submissions will be placed on this website (unless marked confidential or indicated otherwise in the survey or submission form).

Outcomes from the discussion paper will be provided to the Government for consideration.

Audiences

  • Non-government organisations
  • State government agencies
  • Commonwealth agencies
  • Local governments
  • Health professionals
  • Health workforce
  • General public
  • Community groups
  • Businesses
  • Aged care workforce
  • Aged care professionals
  • Health staff
  • HPRG (TGA) Staff
  • Prescription medicines
  • Complementary medicines
  • Over-the-counter medicines
  • Medical Devices & IVDs
  • Biologicals
  • Other

Interests

  • Hospitals
  • Health technology
  • Legislation
  • Regulatory policy
  • Non-prescription medicines
  • Administration
  • Policy Development